glp 1 comparisons differences in drugs GLP-1 Drug Comparison Diabetes and Obesity Treatment New oral GLP-1 drug delivers – Comparative efficacy and safety of

Can Res 62(16):46784684 Mishima K et al (2000) A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide, supplied as a lyophilized powder

The anti-inflammatory pathways modulated by GLP-1 receptor activation (NF-kB suppression, macrophage polarization, Treg enhancement) are largely distinct from the pathways targeted by: Methotrexate: Folate metabolism disruption, different anti-inflammatory pathway TNF inhibitors (adalimumab, etanercept): Direct TNF blockade, whereas GLP-1 reduces TNF production upstream IL-6 inhibitors (tocilizumab): Receptor-level blockade, while GLP-1 reduces IL-6 production JAK inhibitors (tofacitinib, baricitinib): Different signaling pathway entirely Corticosteroids: Broad immunosuppression, while GLP-1 is immunomodulatory This pathway complementarity is why additive benefit is biologically plausible

The impact of clinical nutrition on inflammatory skin diseases

S.SelvinP